Ryosuke Shinouchi

Dr. Ryosuke Shinouchi


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
RSRyosuke Shinouchi
Ryosuke Shinouchi
KSKeita Shibata
Keita Shibata
SJShiori Jono
Shiori Jono
KHKeiji Hasumi
Keiji Hasumi
KNKoji Nobe
Koji Nobe
Diabetic neuropathy (DN) is a major complication of diabetes mellitus. We have previously reported the efficacy of Stachybotrys microspora triprenyl phenol-44D (SMTP-44D) for DN through its potential antioxidant and anti-inflammatory activities. However, the mechanisms underlying the antioxidant and anti-inflammatory activities of SMTP-44D remain unclear. The present study aimed to explore the mechanism of these effects of SMTP-44D in regard to its inhibition of soluble epoxide hydrolase (sEH) in immortalized mouse Schwann cells (IMS32) following high glucose treatment. IMS32 cells were incubated in a high glucose medium for 48 h and then treated with SMTP-44D for 48 h. After incubation, the ratio of epoxyeicosatrienoic acids (EETs) to dihydroxyeicosatrienoic acids (DHETs), oxidative stress markers, such as NADPH oxidase-1 and malondialdehyde, inflammatory factors, such as the ratio of nuclear to cytosolic levels of NF-κB and the levels of IL-6, MCP-1, MMP-9, the receptor for the advanced glycation end product (RAGE), and apoptosis, were evaluated. SMTP-44D treatment considerably increased the ratio of EETs to DHETs and mitigated oxidative stress, inflammation, RAGE induction, and apoptosis after high glucose treatment. In conclusion, SMTP-44D can suppress the induction of apoptosis by exerting antioxidant and anti-inflammatory effects, possibly through sEH inhibition. SMTP-44D can be a potential therapeutic agent against DN.

29 April 2025 in Journal of Diabetes and its Complications
Verified
Journal Article
Closed access
RSRyosuke Shinouchi
Ryosuke Shinouchi
KSKeita Shibata
Keita Shibata
TNTaiju Nagatsuka
Taiju Nagatsuka
KHKeiji Hasumi
Keiji Hasumi
KNKoji Nobe
Koji Nobe

20 February 2023 in Neuroscience Letters
Verified
Journal Article
Closed access
RSRyosuke Shinouchi
Ryosuke Shinouchi
ASAkiko Sasaki
Akiko Sasaki
TTTakashi Takaki
Takashi Takaki
MTMayumi Tsuji
Mayumi Tsuji
YKYuji Kiuchi
Yuji Kiuchi
KNKoji Nobe
Koji Nobe

8 January 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
RSRyosuke Shinouchi
Ryosuke Shinouchi
BTBengisu Turgutalp
Bengisu Turgutalp
RORohini Shivraj Ople
Rohini Shivraj Ople
SEShainnel Eans
Shainnel Eans
AWAshai Kristian Williams
Ashai Kristian Williams
Jay McLaughlinJay McLaughlin
Jay McLaughlin
Background/Objectives: Neuropathic pain remains a significant clinical challenge, with current treatments often providing inadequate relief and adverse effects. Sigma receptors (SRs) modulate nociception and have emerged as potential therapeutic targets for neuropathic pain. Although putative sigma-1 receptor (S1R) ligands have demonstrated analgesic efficacy in preclinical models, their in vivo efficacy and safety profiles require further clarification. Methods: Analogs of well-known selective S1R ligand UVM147 were synthesized using 3-component Ugi reactions and examined in vitro for receptor affinity in radioligand competition binding assays and in vivo with mouse models of neuropathic and inflammatory pain and adverse effects. Results: Three novel heterocyclic compounds (RO-4-3, RO-5-3, and RO-7-3) displayed in vitro nanomolar affinity with varying selectivity for both SR subtypes (S1R and S2R). When screened in vivo at a dose of 30 mg/kg s.c. in mice first subjected to chronic constriction injury (CCI), RO-5-3 and RO-7-3 possessed anti-allodynic potential, while UVM147 was inactive. Upon full characterization, RO-5-3 significantly attenuated mechanical allodynia in a dose-dependent manner, while RO-7-3 was ineffective at higher doses. Both compounds dose-dependently attenuated nociceptive behaviors in the mouse formalin assay. RO-5-3 induced mild respiratory depression without impairing locomotor activity, whereas RO-7-3 caused transient respiratory depression and locomotor impairment. Additionally, RO-5-3, but not RO-7-3, induced conditioned place aversion consistent with potential S2R involvement. Conclusions: RO-5-3 exerts antinociceptive and anti-allodynic effects with minimal adverse behavioral effects, supporting the role of SRs in pain modulation. These results add to growing evidence supporting the development of SR ligands as efficacious therapeutics for neuropathic pain with fewer clinical liabilities.

23 July 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
AWAlaina Waters
Alaina Waters
SLSantiago Iván Loya López
Santiago Iván Loya López
ERErick J Rodriguez-Palma
Erick J Rodriguez-Palma
SEShainnel Eans
Shainnel Eans
RSRyosuke Shinouchi
Ryosuke Shinouchi
Rajesh KhannaRajesh Khanna
Rajesh Khanna
Chronic pain affects hundreds of millions of people and remains poorly managed, as the most effective drugs, including opioids, carry side effects that limit long-term use. Because inflammation drives both the initiation and maintenance of chronic pain, anti-inflammatory mechanisms are an attractive analgesic target. We investigated human alpha-1 antitrypsin (hAAT), a serine proteinase inhibitor with potent anti-inflammatory activity and established protection across disease models, as a candidate analgesic, using Aralast NP®, a clinical-grade, already-approved formulation that makes findings directly translatable. Using calcium imaging and patch-clamp electrophysiology in mouse dorsal root ganglion (DRG) neurons, we found that hAAT reduced activation of low-voltage-activated Ca2+ channels and dampened intrinsic excitability. Veratridine-evoked Ca2+ responses, a sodium-channel-dependent readout of nociceptor activity, were suppressed by hAAT to a degree comparable to the selective sodium channel inhibitors ProTx-II (NaV1.7) and VX-548 (NaV1.8), driven by loss of the nociceptor-associated response profiles. In vivo, hAAT decreased pain sensitivity and pain-associated behaviors in both inflammatory and neuropathic models. Together, these findings reveal a mechanism by which hAAT suppresses nociceptor activity and position Aralast NP® as a safe, effective candidate for treating chronic pain.

1 January 2020 in Proceedings for Annual Meeting of The Japanese Pharmacological Society
Verified
Journal Article
Open access
PDF file
RSRyosuke Shinouchi
Ryosuke Shinouchi
KSKeita Shibata
Keita Shibata
SJShiori Jono
Shiori Jono
THTerumasa Hashimoto
Terumasa Hashimoto
KHKeiji Hasumi
Keiji Hasumi
KNKoji Nobe
Koji Nobe
Diabetic neuropathy (DN) is one of the major complications of the diabetes and has a prevalence as high as 50 % of diabetic patients. However, there are few approved effective therapies against painful or insensate DN. In the present study, we evaluated the effect of SMTP-44D in mice model of DN. SMTP-44D (0.3, 3 and 30 mg/kg) was administered to 200 mg/kg streptozotocin (STZ)-induced diabetic mice from the 1st to the 4th weeks after the injection of STZ. The effect of SMTP-44D was evaluated by mechanical allodynia, thermal hyperalgesia, and velocity of conduction and blood flow of sciatic nerve. Furthermore, levels of inflammatory cytokines and oxidative stress in sciatic nerve by administration of SMTP-44D were assessed by ELISA and TBARS assay, respectively. To assess neurological degeneration, the G-ratio and the myelin thickness of Schwann cells in the sciatic nerve were measured. The treatment with SMTP-44D dose-dependently ameliorated allodynia, hyperalgesia, and velocity of conduction and blood flow of sciatic nerve in diabetic mice of DN. Furthermore, levels of inflammatory factors were also improved. These results indicate that SMTP-44D shows potential as a new therapeutic agent for DN.